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Introduction
Heart and other cardiovascular-associated diseases rank among the 
foremost causes of death worldwide. More people currently suffer from 
cardiovascular diseases (CVD) than from any other disease. According 
to the World Health Organization (WHO), approximately 17.3 million 
people died from CVD in 2008. The number of affected individuals 
is expected to progressively increase in the decades to come. Cardiac 
dysfunction can be due to congenital or acquired heart diseases, which 
often impair the heart valves. Approximately 280’000 heart valve 
replacements are required annually worldwide [1]. Considering the 
aging of the world population, this number is anticipated to triple to 
over 850 000 within five decades [2].
Despite continuous progress in treatment, an ideal therapy has 
not yet been found making this a field of disease with high medical 
relevance. Current best clinical practice consists of surgical prosthetic 
heart valve replacement [3-5]. These valves can be either a mechanical, 
biological allogenic [6,7] or xenogenic [8] prosthesis. Unfortunately 
these replacements suffer from disadvantages associated with clinical 
limitations such as necessary lifelong anti-coagulation treatment, 
risk of immunogenic reactions or adverse reaction such as extensive 
calcification and degradation giving rise to possible reoperations 
[9,10]. Moreover, these prostheses lack the ability of both growth and 
remodeling. 
Heart valve tissue engineering represents a promising solution to 
overcome these limitations of current heart valve substitutes. A major 
focus in heart valve tissue engineering is the in vitro creation of mature 
tissue structures compliant with native valve functionality. Various cell 
types have been investigated for their suitability for heart valve tissue 
engineering including high remodeling capacity of the Extracellular 
Matrix (ECM), including prenatal cells [11-13], umbilical cord [14-
16] and vascular derived cells [17-19]. Furthermore the observed 
multipotency of adult Mesenchymal Stem Cells (MSCs) including 
their ability to differentiate into cells found in the adult heart, such as 
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Abstract
Introduction: A major challenge associated with heart valve tissue engineering is the in vitro creation of mature 
tissue structures compliant with native valve functionality. Various cell types have been investigated for heart valve 
tissue engineering. In addition to prenatal, umbilical cord- and vascular-derived cells, mesenchymal stem cells 
(MSCs) have gained large interest for tissue engineering purposes, because of their broad differentiation potential. 
However, bone marrow derived MSCs require a highly invasive harvesting procedure and decline in both cell number 
and differentiation potential proportionally with the donor’s age. In contrast, adipose derived stem cells (ADSCs) 
represent an interesting alternative. The ease of repeated access to subcutaneous adipose tissue as well as the less 
invasive donation procedures provide clear advantages. Therefore, this study investigated the suitability of ADSCs 
as alternative cell source for tissue engineered heart valves (TEHVs).
Methods: Human ADSCs were seeded on TEHV-scaffolds (n=11) made of nonwoven polyglycolic acid coated with 
poly-4-hydroxybutyrate. TEHVs were cultivated in diastolic-pulse-duplicator-bioreactor systems and subsequently 
seeded with a superficial layer of ADSC-derived endothelial cells. Quantitative assessment of extracellular matrix 
composition of the TEHV-leaflets was performed with biochemical analyses for sulphated glycosaminoglycans, 
hydroxyproline and DNA content. Microstructural evaluation was performed on representative samples of the TEHV-
leaflets by (immuno-)histochemistry and scanning electron microscopy. The mechanical properties of the ADSC 
derived TEHV-leaflets were characterized by biaxial tensile tests.
Results: ADSC-derived TEHV-leaflets showed a homogenous vital cell distribution throughout the whole leaflet 
structure that consisted of large amounts of glycosaminoglycans and collagen and was endothelialized. Furthermore, 
the mechanically stable matrix of the ADSC-derived TEHVs showed a stiffness range in the right order of magnitude 
for heart valve applications.
Conclusion: Human ADSCs represent a promising alternative autologous mesenchymal cell source for TEHVs 
that is of large clinical relevance due to their easy accessibility, efficient proliferation and excellent tissue formation 
capacities.
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cardiomyocytes and endothelial cells, sparked interest to develop them 
for future cell-based therapy such as heart valve engineering. MSCs are 
commonly isolated from the bone marrow and represent a great cell 
source for tissue engineering of living heart valves mainly due to their 
wide availability [14,16,20,21]. However, adult bone marrow derived 
MSCs are suboptimal for clinical use due to the required highly invasive 
donation procedure and the decline in both their proliferation and 
differentiation potential with increasing senescence. In turn, adipose 
derived stem cells (ADSCs) represent a promising alternative cell source 
of mesenchymal origin [22] with comparable differentiation potential. 
Additionally, the ease of repeated accessibility to subcutaneous 
adipose tissue and simple isolation procedures define their superiority 
as alternative clinical cell source. Since human ADSCs have not 
been previously exploited for the generation of Tissue Engineered 
Heart Valves (TEHV), this study investigated their suitability as and 
performance on TEHV scaffolds.
Materials and Methods
Extraction of fat tissue and isolation of adipose derived stem 
cells
Extraction of fat tissue: Human ADSCs were isolated using the 
adipose tissue of patients undergoing plastic surgery (n=20). Samples 
were retrieved following procedures approved by the local ethics 
committee (KEK-ZH-2010-0476/0). 
To harvest the fat tissue, liposuction was performed using the 
tumescent technique. This technique is used to loosen the fat cells 
from the connective tissue and especially to reduce the risk of bleeding. 
Tumescent fluid was injected into the surgical area (basic tumescent 
solution: 1000 ml 0.9% NaCl, 1 ml Kenacort A 10, 12.5 ml NaHCO3, 1 
ml of 1:1000 epinephrine, 50 ml lidocaine 2%) and left there for at least 
30 minutes. Next, blunt Mercedes-cannulas (3 mm in diameter) were 
inserted into the fatty tissue and an excess of adipose tissue was aspirated 
into a glass-container with a vacuum of -80 kPa. The tumescence 
solution was allowed to settle in the collection container allowing for 
the removal of fat tissue supernatant without centrifugation.
Isolation of adipose derived stem cells: ADSCs were isolated 
and prepared as previously described by Digirolamo [23]. Briefly, the 
extracted adipose tissue was collected into a 50 ml Falcon tube and 
digested at 37ºC on a shaker (180 rpm) for 45 minutes with 1 mg/ml 
collagenase Type  A (Roche). The digested sample was then filtered 
through a 40 μm nylon cell strainer. The mononuclear cell fraction 
was isolated by density gradient separation (Ficoll-PaqueTM Plus, 
Amersham Pharmacia Biotech) using standardized protocols [24-
26]. The separated mononuclear cell fraction was cultured in growth 
medium (Dulbecco’s Modified Eagle Medium, DMEM, Sigma), 
supplemented with 2 mM L-glutamine, 50 U/mL penicillin, 50 µg/
mL streptomycin and 10% (v/v) of a selected batch of heat-inactivated 
Fetal Calf Serum (FCS, Gibco) at 37ºC in a humidified atmosphere 
(5% CO2). After 24 hours, the non-adherent cells were discarded and 
adherent cells were washed gently with medium and cultured for ~ 14 
days. Growth medium was replaced twice per week.
Characterization of expanded ADSC
Expression profile of ADSC: ADSC phenotype was determined 
based on the presence of the mesenchymal stem cell antigens CD44 
(Santa Cruz Biotechnologies) and CD73, CD90, CD166 (all Biolegend), 
as well as on the absence of the hematopoietic stem cell markers 
CD34 (Immuno Tools) and CD45 (Biolegend). Isolated cells were 
fixed with 4% paraformaldehyde and then incubated with the primary 
antibodies as specified above. Primary antibodies were detected with 
Cy-2-conjugated affinity-purified goat-anti-mouse antibodies (Jackson 
Immunoresearch Laboratories Inc.). The high-affinity filamentous 
actin (F-actin) probe Alexa 546 phalloidin as well as the nuclear 
counter stain DAPI (4’,6-Diamidino-2-Phenylindole, Sigma) were 
used to counterstain cells (Invitrogen, Life Technologies). Negative 
controls were included by omitting the primary antibodies. Analysis 
was carried out using an inverted fluorescence microscope equipped 
with a CCD camera (Leica Microsystems AG). Image processing was 
performed using the Leica Application Suite processing software (Leica 
Microsystems AG)
For quantitative characterization of the ADSC surface antigen 
expression profile, flow cytometric analysis was performed using the 
primary and secondary monoclonal antibodies described above using 
a FACSCalibur (BD Biosciences) and appropriate scatter gating. $Per 
sample 104 events were acquired.
ADSC differentiation in vitro: To induce differentiation 
into adipocytes and osteocytes, ADSC were plated at a density of 
1000 cells/ cm2. For adipogenic differentiation, ADSC were differentiated 
with 10%  DMEM (see above) supplemented with dexamethasone (1 
µM), insulin (10 µg/mL), indomethacin (120 µM) and 3-Isobutyl-1-
methylxanthine (IBMX, 0.5 mM). 
The osteogenic induction medium contained DMEM supplemented 
with 60 µM ascorbic acid, 10  mM  β-glycerophosphate, 0.1 M 
dexamethasone, 2 mM L-glutamine, penicillin, streptomycin and 15% 
FCS. 
The chondrogenic differentiation was evaluated in 15 mL conical 
tubes with 2 x 105 cells/ mL in DMEM medium supplemented with 2 
mM L-glutamine, 1% FCS, 10 ng/mL TGF-β, 50 µM ascorbic acid and 
0.5 µg/mL insulin. 
To induce endothelial differentiation, ADSCs were exposed to 
basal medium (EBMTM-2, Cambrex), containing Vascular Endothelial 
Growth Factor (VEGF), Human Fibroblast Growth Factor (hFGF), 
human recombinant long R3 Insulin-Like Growth Factor-1 (R-3-
IGF-1), Human Epidermal Growth Factor (hEGF), Gentamycin and 
Amphotericin (GA-1000), hydrocortisone, heparin, ascorbic acid, and 
5% FCS. All induction media, summarized in Table 1, were replaced 
three times a week. 
Condition Medium Serum Supplements
Control DMEM 10% none
Adipogenic DMEM 10% dexamethasone (1 µM), insulin (10 µg/mL), indomethacin (120 M), 3-Isobutyl-1-methylxanthine (IBMX, 0.5 mM) 
Osteogenic DMEM 15% 60 µM ascorbic acid, 10 mM β-glycerophosphate, 0.1 µM dexamethasone, 
Chondrogenic DMEM 1% 10 ng TGF-β, 50 µM ascorbic acid and 0.5 µg/mL insulin. 
Endothelial EBMTM-2 5%
vascular endothelial growth factor (VEGF), human fibroblasts growth factor (hFGF), human recombinant long insulin-like 
growth factor-1 (R-3-IGF-1), human epidermal growth factor (hEGF), gentamycin and amphotericin (GA-1000), hydrocortisone, 
heparin, ascorbic acid
Table 1: Medium compositions for differentiation of human adipose derived stem cells.
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Histology: The adipogenic, osteogenic and chondrogenic 
differentiation cultures were harvested after 21 days washed in PBS and 
fixed in 4% formalin before further histological analysis. 
To detect the lipid vacuoles after adipogenic stimulation, cells were 
stained with Oil Red-O (3 mg/mL, Sigma). Calcium deposits arising 
during osteogenic differentiation were identified with 2% Alizarin 
Red S (pH 4.2, Fluka). Chondrogenic cultures were embedded in 
paraffin and sectioned at 5 µm thickness. For histological evaluation 
of cartilage-specific proteoglycans, sulfated glycosaminoglycans (GAG) 
were visualized with 0.1% Toluidine blue (Sigma-Aldrich) in 1% 
sodium borate. In addition, ADSCs were analyzed for their endothelial 
differentiation potential using a tube formation assay. For this purpose 
1.5 x 104 cells were seeded on a 96-well-plate coated with 80 µl Matrigel 
(BD Biosciences) and photographs depicting capillary tube formation 
were taken after 10 h and 24 h of incubation.
Tissue engineering of heart valves
Fabrication of heart valve scaffolds: The trileaflet heart valve 
scaffolds (n=11), were produced from nonwoven polyglycolic acid 
meshes (PGA) with a thickness of 1.0 mm and a density of 70 mg/cm3 
(Cellon). The scaffold was integrated into a self-expandable nitinol 
stent with an outer diameter of 30 mm (pfm AG) by sewing the scaffold 
molds onto the inner surface of the stent struts. Then, the scaffold-stent-
construct was coated by dipping them into the biologically derived 
and rapidly degradable biopolymer poly-4-hydroxybutyrate (P4HB, 
1, 75%, Tepha Inc.) in Tetrahydrofuran (THF, Fluka). After solvent 
evaporation, physical bonding of adjacent fibers and continuous coating 
was achieved. After evaporation of the THF, the produced heart valve 
construct was sterilized with ethylene oxide. The solvent was allowed to 
evaporate to reduce any toxic reaction to the cells before the scaffold was 
washed twice in PBS. Prior to cell seeding the scaffolds were incubated 
in tissue engineering (TE)-medium, DMEM growth medium listed 
above additionally supplemented with 0.1% FCS, 1% GlutaMax, 1% 
Penicillin-streptomycin and L-ascorbic acid 2-phosphate (0.25 mg/mL; 
Sigma-Aldrich) overnight.
Seeding of heart valves: For seeding onto the PGA/P4HB scaffold 
ADSC were diluted to a final concentration of 1.5 x 106 cells /cm2 in fibrin 
glue. To ensure homogeneous distribution throughout the scaffold the 
cells were first re-suspended in the thrombin component (10 IU, Sigma) 
and then quickly and thoroughly mixed with the fibrinogen component 
(10 mg protein, Sigma) and finally applied onto the scaffold construct.
Cultivation of the heart valves: After seeding, the heart valves were 
placed into a diastolic pulse duplicator system, previously described 
in detail [27]. This strain-based conditioning approach uses dynamic 
strains for cultivation of the TEHV with an additional continuous 
perfusion loop (4 mL/min) to ensure a closed system. The leaflets 
were exposed to dynamic strains by applying increasing transvalvular 
pressure differences. After 5 days of culture with only perfusion and no 
transvalvular pressure differences, the system started with 3 mm Hg, 
increased up to 15 mm Hg in the 4 following days and remained at that 
pressure until the end of the culture (day 28). TE-medium was replaced 
every 4 days. 
Endothelialization of the TEHVs: After 4  weeks of culturing, 
TEHVs (n=3) were endothelialized with 0.2 x 106 ADSC derived 
endothelial like cells per cm² scaffold. Subsequently, TEHVs were 
further kept under dynamic culture conditions for another 48 hours in 
endothelial differentiation medium to ensure adequate cell attachment. 
Thereafter, heart valves were harvested from the bioreactor system and 
analyzed accordingly.
Analysis of tissue engineered heart valves
Histological and immunohistochemical staining: For qualitative 
evaluation, representative samples of the cultivated TEHVs were fixed 
with 4% formalin, embedded in paraffin and cut into 5 µm sections. To 
assess the tissue composition, the slides were stained with Haematoxylin-
Eosin, Masson-Trichrome, Elastica-van-Gieson and von Kossa.
To determine the potential alteration of the seeded cells after 
cultivation, the slides were immunohistochemically analyzed using 
specific antibodies for vimentin, alpha smooth muscle actin (a-SMA, 
Dako) and the endothelial marker CD31 (Biolegend). Primary 
antibodies were detected by use of Diaminobenzidine (DAB, 
Histochemistry Kit, Molecular Probes).
Scanning electron microscopy: To evaluate the ultra-structural 
morphology of cells growing in the PGA/P4HB matrix, representative 
TEHV tissue samples were analyzed by Scanning Electron Microscopy 
(SEM). Tissue samples were fixed in 2% (v/v) glutaraldehyde with 0.1% 
cacodylate (PH 7.3). After preparation, samples were sputtered with 
gold and investigated using a Zeiss Supra 50 VP Microscope (Zeiss).
Extracellular matrix production: To determine the major tissue 
structures responsible for native valve function, Extracellular Matrix 
(ECM) production was assessed by biochemical assays. To deduce 
the cell number on the scaffold, the content of total Deoxyribonucleic 
Acid (DNA) was analyzed as an indirect indicator. For measuring DNA 
amounts, the Hoechst dye method [28] was used and DNA content 
inferred from a standard curve prepared from calf thymus DNA 
(Sigma). The amount of produced collagen structures was determined 
by analyzing hydroxyproline (HYP) and sulfated glycosaminoglycan 
(GAG) content. HYP content was determined from lyophilized samples 
with a modified version of the protocol described by Huszar et al. [29] 
with trans-4-hydroxy-L-proline (Sigma) as standard. Sulphated GAG 
content was colorimetrically calculated using a chondroitin-6-sulfate 
from shark cartilage (Sigma) as standard [30]. The DNA, GAG and HYP 
content was normalized to the mg of dry tissue weight and standardized 
to native tissue.
Biomechanical analysis: The mechanical properties of the ADSC 
TEHV samples were analyzed with a biaxial tensile tester (BioTester, 5 
N load cell; CellScale, Waterloo, Canada) in combination with LabJoy 
software (V8.01, CellScale). Two square samples of 36 mm2 each were 
symmetrically cut from one ADSC TEHV leaflet, taking into account 
the radial and circumferential orientation. Sample thickness was 
measured prior to testing. Samples were mounted onto the biaxial 
tensile tester, resulting in an effective test surface area of 12.25 mm2. 
A custom programmed protocol was stretching the sample equally 
biaxial in both radial and circumferential direction up to 30% strain at 
a strain rate of 1.66% per second. After stretching, the sample recovered 
directly back to 0% strain at a strain rate of 1.66% per second, followed 
by a rest cycle of 54 seconds. Prior to measuring the final stresses, 
the sample was preconditioned for 5 cycles. A high order polynomial 
curve was fitted through each individual data set in both radial and 
circumferential direction. The stiffness of the tissue was represented by 
the tangent modulus and was calculated as the slope from the tangent 
to the fitted polynomial curve at 30% strain. 
Statistical analysis
Biochemical measurements and quantitative biomechanical data 
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are represented as mean ±  standard deviation. Paired t-tests were 
performed to test for differences between ECM group means (SPSS17.0, 
IBM, Somers, NY, USA).
Results
Morphology and phenotype of adipose derived stem cells
In this study, a cell population of mesenchymal origin obtained 
from human adipose fat tissue was examined concerning the 
multilineage potential. Human adipose tissue was obtained by 
liposuction (n=20) from female patients of 49 ± 8 years of age. 
Approximately 0.5  x  106 mononuclear cells/g tissues were isolated 
independent of source type and subsequently cultured under 
standard conditions (10% DMEM). In culture the cells attached 
to the bottom of the culture flask and assumed a fibroblast-like 
morphology. This morphology was maintained through repeated 
subcultures under expansion conditions; no other cell morphology 
was observed. During the subsequent 4 passages an average doubling 
time of 1.5 days was observed (data not shown). Neither source type, 
age nor body mass index (BMI) influenced the population doubling 
rate.
Figure 1: Expression profile of human adipose derived stem (ADSC). Flow cytomtery analysis revealed ADSC to be positive for CD166, CD90, CD73 and CD44, but 
negative for hematopoietic surface markers CD34 and CD45 (A). The immunofluorescence staining supported these results (B). The cells were stained with DAPI 
(blue) to identify the nuclei of the cells and with phalloidin to show the actin filament of the cells (red). The series of the CD proteins were stained in green. The three 
staining are merged in the last column.
Figure 2: Differentiation assays. Cell differentiation of human adipose derived 
stem cells along the osteogenic (A), adipogenic (B), chondrogenic (C) and 
endothelial (D) pathways were detectedfollowing stainings with Alizarin Red S 
(A), Oil red (B) and Toluidine blue (C). The endothelial like differentiation was 
demonstrated by the tube formation assay (D).
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Characterization of expanded ADSC
Samples were analyzed by flow cytometry using the specific 
combination of mesenchymal stem cell surface markers to determine 
ADSC composition quantitatively. The analysis revealed ADSC to be 
positive for CD166 (73.8 ± 5.5%), CD90 (98.0 ± 0.4%), CD73 (91.0 ± 
0.5%) and CD44 (98.8 ± 0.2%), but negative for hematopoietic surface 
markers CD34 (4.4 ±1.5%) and CD45 (0.4 ± 0.3%) (Figure 1A). The 
immunofluorescence staining supported these results (Figure 1B). The 
cells kept their stem cell character up to passage 5 under proliferation 
conditions (10% DMEM).
Multilineage capacity of ADSC was then asserted using adipogenic, 
osteogenic, chondrogenic as well as endothelial-like differentiation 
assays with lineage specific induction factors (Table 1). Calcium 
deposits and lipid vacuoles were detected 3 weeks after induction 
using Alizarin Red S and Oil Red-O staining, and revealed that ADSC 
had differentiated toward the osteogenic and adipogenic lineages, 
respectively (Figure 2A and 2B). 
ADSC initially grown in a monolayer were also cultivated in 3D 
spheres for 3 weeks, which is known to facilitate chondrogenesis [31]. 
Toluidin blue staining confirmed the production of cartilaginous matrix 
and hence the chondrogenic phenotype (Figure 2C). Differentiation 
of ADSC into functional endothelial like cells was investigated by 
performing a tube formation assay. The observed tube formation after 
10 hours was comparable to freshly isolated endothelial cells from 
human umbilical cord (Figure 2D). 
Analysis of tissue engineered heart valve leaflets
Macroscopic appearance: TEHV based on PGA/P4HB were 
seeded with human adult ADSC and cultivated using diastolic pulse 
duplicator systems to evaluate the cellular behavior on 3D formation 
[27]. This system mimics the diastolic phase in a closed leaflet culture by 
applying pressure, which acts on the surface of the leaflets resulting in 
tissue straining. The macroscopy of the ADSC-TEHV presented intact 
TEHVs with smooth and shiny tissue formation and homogeneous 
thickness after 4 weeks of cultivation (Figure 3A). However, dissection 
of the merged TE leaflets after culture revealed slight retraction (Figure 
3B).
Histological and immunohistochemical stainings and scanning 
electron microscopy: Microstructural features of representative 
tissue samples of the ADSC derived TE leaflets were analyzed both 
by histological and immunochemical staining procedures (Figure 4) 
as well as by scanning electron microscopy (Figure 5). Haematoxylin 
Eosin staining demonstrated appropriate tissue formation with well-
developed outer layers and little cellularity in the inner part of the 
TEHVs (Figure 4A). Furthermore, effective tissue formation with 
collagen fibers was shown in Masson Goldner (Figure 4C) staining 
Figure 3: Macroscopic analysis of the tissue engineered heart valve based on 
adipose derived stem cells after 4 weeks of cultivation in the strain bioreactor 
system: Tissue engineered heart valve integrated in the Nitinol stent (A). After 
dissection of the merged TE leaflets (B) slight retraction of the leaflets revealed.
Figure 4: Microscopic analysis of the tissue engineered leaflets: The 
histological staining’s (A: HE, B: Elastica van Gieson, C: Masson Goldner, D: 
alpha smooth muscle actin, E: Vimentin, F: von Figure Legend Kossa) of the 
tissue engineered heart valve leaflets showed a good cell distribution (A), well 
developed outer layers but less cellularity in the inner part as well as a good 
extracellular matrix formation (B). After in vitro conditioning no elastic fibres 
(C) were detectable. The samples showed a pronounced a-SMA positive layer 
(D) and vimentin positive cells were detectable (E). Also no calcification was 
detectable after in vitro cultivation (F).
Figure 5: Endothelialisation: The ultra-structural analysis using SEM showed 
a densely covered surface of the tissue engineered heart valve leaflets and 
spindle shaped cells when seeded with human adipose derived stem (ADSC) 
(A). In contrast endothelial structures were visible after coating with ADSC 
derived endothelial-like cells (B). This superficial endothelial cell lining were 
also confirmed by the immuno-histological detection of the endothelial marker 
CD31 (C).
Figure 6: Extracellular matrix of the tissue engineered (TE) leaflets: The 
contents of DNA, glycosaminoglycanes (GAG) and hydroxyprolines (HYP) in 
the TE leaflets (B column) were compared with native leaflet tissue (A column). 
(n.s.: non-significant; * significant for P=0.05-level).
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and a relatively high amount of α-smooth muscle actin (α-SMA) was 
detected within the neo-tissue (Figure 4D). The intermediate filament 
protein vimentin, predominantly found in cells of mesenchymal 
origin, was expressed throughout the entire TEHV tissue (Figure 4E). 
However, elastic fibers were undetectable by the Elastica van Gieson 
staining after the in vitro conditioning in the bioreactor system (Figure 
4B). The ultra-structural analysis using SEM showed a densely covered 
surface of the TEHV leaflets with extracellular matrix elements and 
spindle shaped cells when seeded with ADSC (Figure 5A). Moreover 
after additional coating with ADSC derived endothelial-like cells, a 
cobble stone pattern on the tissue surface was observed (Figure 5B). 
This superficial endothelial cell lining was also confirmed by the 
positive detection of the endothelial marker CD31 on the surfaces of 
the TE leaflets (Figure 5C). 
ECM components: Next, neo-tissue ECM composition of the 
ADSC derived TEHV leaflets was biochemically analyzed using HYP, 
GAG and DNA assays. TEHV leaflets showed on average of 28.9 µg 
HYP per mg dry tissue, which corresponds to about 65% of native 
heart valve tissue, implying that the collagen content is significantly 
lower in tissue engineered when compared to native heart valves 
(p<0.05). The GAG and DNA content amounted to 19.7 µg and 3.1 
µg per dry tissue, respectively. These values correspond to 50% GAG 
(p<0.05) and 88% DNA (p>0.05) when compared to native valve 
tissue (Figure 6).
Biomechanical behavior: Equal biaxial tensile tests were executed 
up to a strain of 30% to investigate the biomechanical behavior of 
the ADSC TEHVs. The stress-strain curves and calculated tangent 
moduli are shown in both radial and circumferential direction in 
Figure 7. The tangent moduli are 2.66 ± 0.43 MPa and 2.45 ± 0.51 MPa 
in radial and circumferential direction, respectively. No significant 
difference in tissue stiffness can be observed between both radial and 
circumferential direction. Therefore, isotropy of the material may be 
assumed.
Discussion
As a novel and clinically interesting cell source in regenerative 
medicine, adipose tissue seems to be a rich source of multipotent 
adipose tissue-derived mesenchymal stem cells. In order to evaluate 
ADSC as an alternative cell source for the production of TEHV, 
adult ADSC were isolated from fat suction from plastic surgery and 
characterized. The cells exhibited the characteristics of mesenchymal 
stem cells regarding their differentiation capacity into the osteogenic, 
adipogenic, chondrogenic and endothelial-like lineage. Furthermore, 
the stem cell specific combination of surface markers was detectable 
by immunohistochemical staining’s as well as by flow cytometry. 
According to current literature the anatomical site of the adipose 
tissue does not affect the total number of viable cells that can be 
obtained from the subcutaneous fatty tissue [32,33]. Compared with 
mesenchymal stem cells from bone marrow biopsies, ADSC show 
also no statistically significant correlation between ADSC stem cell 
quality, proliferation capacity and the patient’s age [34]. Additionally, 
ADSC implicate an equal differentiation potential into cells and 
tissues of mesenchymal origin [35]. However, the proportion of 
ADSC (hip/thigh) is much higher than the frequency of MSC in bone 
marrow, which is lower than 0,001%-0,01% [36]. Taken together, fat 
tissue is a promising and clinical highly relevant source for isolating 
mesenchymal stem cells in large quantities with comparable cell 
quality. 
Accordingly, clinical applications for cell therapy and tissue 
engineering using ADSC are highly promising and have already 
been used successfully in a variety of clinical trials, especially in 
tissue reconstruction. The first clinical trials were already initiated at 
the beginning of the 21st century. There the feasibility and safety of 
autologous ADSC transplantation were tested, e.g. in peripheral nerve 
repair [37], treatment of Crohn´s disease fistulas [38], osteogenesis 
imperfecta [39], bladder diseases, urethral sphincter dysfunction 
associated with birth trauma and hormonal deficiency as well as the 
Figure 7: Equal biaxial tensile results of ADSC TEHV leaflets. Left: the tangent modulus of the samples at 30% strain in both radial and circumferential direction. 
Right: the equal biaxial tensile curves after preconditioning in both radial and circumferential direction, up to a strain of 30%. (n.s.: non-significant).
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regeneration of bladder tissues [40]. Further studies substantiated the 
therapeutic potential of ADSC by transplanting them in a setting of 
chronic heart failure [41] or Acute Myocardial Infarction (AMI). After 
cell transplantation into the myocardial scar tissue in rabbit and porcine 
models, ADSC formed cardiac islands and vessel-like structures, 
induced angiogenesis and improved cardiac function with no report 
of potentially severe arrhythmias [42,43]. The APOLLO trial, a “first-
in-man”, prospective, double blind, randomized and placebo-controlled 
trial, demonstrated the safety and feasibility of ADSC transplantation in 
patients with acute myocardial infarction [43]. 
In the field of cardiovascular surgery, Taylor et al. in 2011 were the 
first to report that ADSC respond to mechanical stimulations/stress in 
a similar manner as valve interstitial cells, e.g. by secreting collagen. 
It was demonstrated that stretching increased the incorporation 
of hydroxyproline in ADSC, which was followed by the enhanced 
production of collagen and elastin crosslinks. This observation 
represents a fundamental mechanism which is essential to maintain the 
load capacity of leaflets and allows therewith valve functionality [44]. 
In the present study, after four weeks bioreactor cultivation, TEHV 
based on ADSC consisted on average of 29 µg collagen (HYP) per mg 
dry tissue, which is 65% of the values of native valves. Previous studies 
that used e.g. amniotic fluid derived stem cells for TEHV production, 
only reached up to 3 µg HYP (2.5% of the value of native tissue) [13]. 
Collagen is the most copious protein in cardiovascular tissue and is 
essential to provide tensile strength in an organized scaffold. Also, the 
ECM component elastin in the TEHV is of particular importance for 
the biomechanical behavior of the valves [45]. Without the mechanical 
component elastin, the mechanical behavior of native valve cusp will 
be altered, primarily by reducing the valve’s extensibility and increasing 
their stiffness in the radial direction [46]. Using the histological Elastica 
van Gieson staining, an elastin network was not detectable after in vitro 
conditioning in the bioreactor system in the present study. However this 
in vitro observation is only of minor impact due to elastin production 
after transplantation which occurred in in vivo studies already 20 weeks 
after implantation [17].
From the biomechanical analyses it cannot be concluded if these 
valves are functional under pulmonary conditions. However, the tissue 
stiffness range is in the right order of magnitude [47,48], which suggests 
that the TEHVs may perform appropriately in vivo. 
The necessity of endothelialization of tissue engineered heart valves 
is still highly controversial. Endothelialization of grafts can improve 
their long term patency and prevent thrombogenesis [49]. However, 
in vitro endothelialization of grafts involves multiple additional 
procedures, for instance donation of patient specific tissue for isolation 
of endothelial cells. In vivo studies showed that implantation of non-
endothelialized TEHV resulted in almost confluent endothelialization 
already after 4-8 weeks in vivo [16,48,50,51]. However, using ADSC 
for tissue engineering would enable the endothelialization after 
differentiation of the cells in the presence of vascular endothelial growth 
factor without requiring any surgical harvesting of additional patient-
specific tissues. In the present study, the endothelial surface layer on 
the TEHV wall as well as on the valvular leaflets was detected by the 
immunohistochemical staining with the endothelial marker CD31 as 
well as by ultra-structural analysis (SEM). 
After separation of the TE leaflets (which is a prerequisite before 
implantation), retraction of valve leaflets occurred, which might 
affect functionality of the valves. This phenomenon, which was also 
observed in TEHV based on other cell types [52,53], might be the 
result of the complete relaxation of the stent after harvest or of the 
relatively high amount of α-SMA. Elimination of cellular components 
(decellularization) of the TEHV might strongly reduce this problem, 
without altering the collagen structure or tissue strength [47]. As 
a result, the decellularised TEHV (dTEHV) would not show any 
retraction of leaflets after separation. Moreover, decellularization would 
enable on-the-shelf storage of the TEHV and simplify the logistic of 
TEHV implantations. Prior to implantation, dTEHV could be loaded 
with autologous less contractile cells, endowed with a reservoir of 
soluble factors that can exert paracrine effects on other cells ingrowth 
resulting in remodelling stimulation. 
Conclusion
The aim of the present study was to evaluate the feasibility of 
autologous Adipose Derived Stem Cells (ADSC), obtained through 
plastic surgery fat harvesting in combination with the fast degrading 
scaffold material PGA/P4HB for the in vitro generation of tissue 
engineered heart valves. 
The simple and minimally invasive surgical procedure, the easy 
and repeatable access to the subcutaneous adipose tissue, and the 
uncomplicated enzyme-based isolation procedures make this tissue 
source of MSC most attractive for clinical application. Therefore, ADSC 
represent an alternative source of autologous adult stem cells that can 
be obtained repeatedly in large quantities under local anesthesia with a 
minimum of donor-site morbidity.
TEHV based on human adult ADSC after cultivation using strain 
bioreactors showed a good and vital cell distribution throughout the 
whole tissue structure. Furthermore, a mechanically stable isotropic 
matrix with collagen production was built, producing a tissue stiffness 
in the right order of magnitude for heart valve applications [47]. These 
preliminary results indicate that ADSC represent an auspicious cell 
type for the production of tissue engineered heart valves, in particular 
due to their capacity to synthesize and remodel extracellular matrix, 
and to respond to biophysical and biochemical stimuli.
However, despite the promising outcomes, the biologic mechanisms 
that underlie the therapeutic success of stem cell transplantations are 
still unknown [54]. The successful generation of functional TEHV 
based on ADSC clearly demands further experiments including work 
on animal models before successful clinical application. Our data will 
be of key relevance for promoting the efficiency of stem cell therapy.
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